Landscape of transarterial chemoembolization represented interventional therapy for hepatocellular carcinoma

Yang-Yang Fu; Wen-Mao Li; Hong-Qiao Cai; Yan Jiao

doi:10.4240/wjgs.v16.i12.3903

Landscape of transarterial chemoembolization represented interventional therapy for hepatocellular carcinoma

World J Gastrointest Surg. 2024 Dec 27;16(12):3903-3906. doi: 10.4240/wjgs.v16.i12.3903.

Authors

Yang-Yang Fu¹, Wen-Mao Li², Hong-Qiao Cai³, Yan Jiao⁴

Affiliations

¹ Department of The First Operation Room, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
² Department of Rehabilitation, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China.
³ Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
⁴ Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China. [email protected].

Abstract

This article discusses the article written by Tan et al. Transarterial chemoembolization (TACE) is one of the main treatment methods for advanced hepatocellular carcinoma (HCC). There are other vascular interventional therapies, including drug-eluting bead TACE, transarterial radioembolization, and hepatic arterial infusion chemotherapy. TACE combined with anti-angiogenesis therapy may improve tumor control and prolong progression free survival. The combination therapy of TACE and immunotherapy may improve the clinical efficacy of HCC. In future research, more basic and clinical studies are needed to explore the immunogenic intervention therapy.

Keywords: Anti-angiogenesis; Hepatocellular carcinoma; Immunotherapy; Interventional therapy; Programmed cell death 1; Transarterial chemoembolization.